Monoclonal gammopathy of undetermined significance and risk of venous thromboembolism

European Journal of Haematology

Volumn 86, Issue 2, 2011, Pages 129-134

  Gregersen, Henrik ^a   Nørgaard, Mette ^b   Severinsen, Marianne T ^a   Engebjerg, Malene C ^b   Jensen, Paw ^a   Sørensen, Henrik T ^b  

^a AALBORG UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Incidence rate ratios; Monoclonal gammopathy of undetermined significance; Multiple myeloma; Population based study; Risk; Venous thromboembolism

Indexed keywords

IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M;

ADULT; ARTICLE; COHORT ANALYSIS; COMORBIDITY; DENMARK; DISEASE COURSE; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; MONOCLONAL IMMUNOGLOBULINEMIA; MORTALITY; MULTIPLE MYELOMA; POPULATION RESEARCH; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; REGRESSION ANALYSIS; RISK ASSESSMENT; VENOUS THROMBOEMBOLISM;

AGED; COHORT STUDIES; COMORBIDITY; DENMARK; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; PARAPROTEINEMIAS; PROPORTIONAL HAZARDS MODELS; RISK; RISK FACTORS; VENOUS THROMBOEMBOLISM;

EID: 78651419162     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2010.01539.x     Document Type: Article

References (24)

1. Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Offord JR, Dispenzieri A, Katzmann JA, Melton LJ 3rd. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med 2006;354:1362-9.
2. Kyle RA, Therneau TM, Rajkumar SV, Offord JR, Larson DR, Plevak MF, Melton LJ 3rd. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 2002;346:564-9.
3. Blann AD, Lip GYH. Venous thromboembolism. BMJ 2006;332:215-9.
4. Cohen AT, Alikhan R, Arcelus JI, Bergmann JF, Haas S, Merli GJ, Spyropoulos AC, Tapson VF, Turpie AG. Assessment of venous thromboembolism risk and the benefits of thromboprophylaxis in medical patients. Thromb Haemost 2005;94:750-9.
5. Blom JW, Doggen CJM, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations and the risk of venous thrombosis. JAMA 2005;293:715-22.
6. Palumbo A, Rajkumar SV, Dimopoulos MA, et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 2008;22:414-23.
7. Schütt P, Ebeling P, Buttkereit U, et al. Thalidomide in combination with vincristine, epirubicin and dexamethasone (VED) for previously untreated patients with multiple myeloma. Eur J Haematol 2005;74:40-6.
8. Sallah S, Husain A, Wan J, Vos P, Nguyen N. The risk of venous thromboembolic disease in patients with monoclonal gammopathy of undetermined significance. Ann Oncol 2004;15:1490-4.
9. Srkalovic G, Cameron MG, Rybicki L, Deitcher SR, Kattke-Marchant K, Hussein MA. Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease. Cancer 2004;101:558-66.
10. Kristinsson SY, Fears TR, Gridley G, Turesson I, Mellqvist UH, Björkholm M, Landgren O. Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma. Blood 2008;112:3582-6.
11. Cohen AL, Sarid R. The relationship between monoclonal gammopathy of undetermined significance and venous thromboembolic disease. Thromb Res 2010;125:216-9.
12. Kristinsson SY, Pfeiffer RM, Bjorkholm M, Goldin LR, Schulman S, Blimark C, Mellqvist UH, Wahlin A, Turesson I, Landgren O. Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study. Blood 2010;115:4991-8.
13. Bida JP, Kyle RA, Therneau TM, Melton LJ, Plevak MF, Larson DR, Dispenzieri A, Katzmann JA, Rajkumar SV. Disease associations with monoclonal gammopathy of undetermined significance: a population-based study of 17.398 patients. Mayo Clin Proc 2009;84:685-93.
14. Frank L. Epidemiology. When an entire country is a cohort. Science 2000;287:2398-9.
15. Andersen TF, Madsen M, Jørgensen J, Mellemkjaer L, Olsen JH. The Danish National Hospital Register. A valuable source of data for modern health science. Dan Med Bull 1999;46:263-8.
16. Storm HH, Michelsen EV, Clemmensen IH, Pihl J. The Danish Cancer Registry - history, content, quality and use. Dan Med Bull 1997;44:535-9.
17. Gregersen H, Mellemkjaer L, Ibsen JS, Sorensen HT, Olsen JH, Pedersen JO, Dahlerup JF. Cancer risk in patients with monoclonal gammopathy of undetermined significance. Am J Hematol 2000;63:1-6.
18. Nickelsen TN. Data validity and coverage in the Danish National Health Registry. A literature review. Ugeskr Laeger 2001;164:33-7.
19. Severinsen MT, Kristensen SR, Overvad K, Dethlefsen C, Tjønneland A, Johnsen SP. Venous thromboembolism discharge diagnoses in the Danish National Patient Registry should be used with caution. J Clin Epidemiol 2010;63:223-8.
20. Sorensen HT, Horvath-Puho E, Pedersen L, Baron JA, Prandoni P. Venous thromboembolism and subsequent hospitalisation due to acute arterial cardiovascular events: a 20-year cohort study. Lancet 2007;370:1773-9.
21. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83.
22. Kyle RA, Rajkumar V, Lust JA. Monoclonal gammopathy of undetermined significance and smouldering multiple myeloma. In: Greer JP, Foerster J, Lukens JN, Rodgers GM, Paraskevas F, Glader B, eds. Wintrobe's Clinical Hematology, 11th edn. Philadelphia: Lippincott Williams & Wilkins; 2004:2565-81.
23. Colls BM, Lorier MA. Immunocytoma, cancer and other associations of monoclonal gammopathy: a review of 224 cases. N Z Med J 1975;82:221-6.
24. Zangari M, Tricot G, Polavaram L, et al. Survival effect of venous thromboembolism in patients with multiple myeloma treated with lenalidomid and high-dose dexamethasone. J Clin Oncol 2010;28:132-5.